Database references:

Citations

• 2011. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes. The Medical Letter On Drugs and Therapeutics. 53(1367).
• Agrawal, R, et al. 2012. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. Current Drug Targets. 13(7).
• Aletti, R, et al. 2011. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Cardiology in Review. 20(1).
• Aronson, R, et al. 2012. Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. Expert Opinion On Pharmacotherapy. 13(10).
• Barnett, AH, et al. 2011. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Advances in Therapy. 28(6).
• Barnett, AH, et al. 2012. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes, Obesity & Metabolism. 14(12).
• Blech, S, et al. 2010. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38(4).
• Chen, L, et al. 2012. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Current Molecular Medicine. 12(8).
• Christensen, M, et al. 2012. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride? Nature Reviews. Endocrinology. 8(10).
• Deacon, CF, et al. 2009. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opinion On Investigational Drugs. 19(1).
• Deeks, ED, et al. 2012. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 72(13).
• Del Prato, S, et al. 2011. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity & Metabolism. 13(3).
• Del Prato, S, et al. 2011. Linagliptin for the treatment of type 2 diabetes. Expert Opinion On Pharmacotherapy. 12(17).
• Forst, T, et al. 2010. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine : A Journal of the British Diabetic Association. 27(12).
• Forst, T, et al. 2011. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism. 13(6).
• Forst, T, et al. 2011. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opinion On Pharmacotherapy. 13(1).
• Freeman, MK, et al. 2012. Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus. P & T : A Peer-reviewed Journal For Formulary Management. 36(12).
• Friedrich, C, et al. 2011. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 36(1).
• Friedrich, C, et al. 2011. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. Clinical Drug Investigation. 31(9).
• Fuchs, H, et al. 2011. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 45(5).
• Gallwitz, B, et al. 2012. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet (London, England). 380(9840).
• Gallwitz, B, et al. 2012. Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy. Clinical Medicine Insights. Endocrinology and Diabetes. 5.
• Ghatak, SB, et al. 2011. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. Current Diabetes Reviews. 7(5).
• Gomis, R, et al. 2011. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity & Metabolism. 13(7).
• Gomis, R, et al. 2012. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice. 66(8).
• Graefe-Mody, EU, et al. 2009. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Current Medical Research and Opinion. 25(8).
• Graefe-Mody, EU, et al. 2010. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 48(10).
• Graefe-Mody, EU, et al. 2011. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 49(5).
• Graefe-Mody, U, et al. 2010. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. International Journal of Clinical Pharmacology and Therapeutics. 48(6).
• Graefe-Mody, U, et al. 2010. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metabolism and Pharmacokinetics. 26(2).
• Graefe-Mody, U, et al. 2011. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes, Obesity & Metabolism. 13(10).
• Graefe-Mody, U, et al. 2011. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clinical Therapeutics. 33(8).
• Graefe-Mody, U, et al. 2012. Pharmacokinetics of linagliptin in subjects with hepatic impairment. British Journal of Clinical Pharmacology. 74(1).
• Graefe-Mody, U, et al. 2012. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clinical Pharmacokinetics. 51(7).
• Greischel, A, et al. 2010. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38(9).
• Haak, T, et al. 2012. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity & Metabolism. 14(6).
• Heise, T, et al. 2009. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes, Obesity & Metabolism. 11(8).
• Hocher, B, et al. 2012. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. International Journal of Cardiology. 167(1).
• Horie, Y, et al. 2009. Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo. Trials. 10.
• Horie, Y, et al. 2011. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clinical Therapeutics. 33(7).
• Hussar, DA, et al. 2011. Vilazodone hydrochloride, linagliptin, and alcaftadine. Journal of the American Pharmacists Association : JAPhA. 51(4).
• Jelsing, J, et al. 2012. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. The Journal of Endocrinology. 214(3).
• Johansen, OE, et al. 2012. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular Diabetology. 11.
• Kalra, S, et al. 2011. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications. Recent Patents On Endocrine, Metabolic & Immune Drug Discovery. 5(3).
• Kawamori, R, et al. 2011. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes, Obesity & Metabolism. 14(4).
• Kern, M, et al. 2012. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PloS One. 7(6).
• Klein, T, et al. 2012. Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. Diabetes, Obesity & Metabolism. 14(11).
• Lewin, AJ, et al. 2012. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 34(9).
• McGill, JB, et al. 2012. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 36(2).
• Neumiller, JJ, et al. 2012. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. The Annals of Pharmacotherapy. 46(3).
• Neumiller, JJ, et al. 2012. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clinical Therapeutics. 34(5).
• Ohmura, T, et al. 2012. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)]. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 139(4).
• Owens, DR, et al. 2011. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabetic Medicine : A Journal of the British Diabetic Association. 28(11).
• Rauch, T, et al. 2012. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. 3(1).
• Rendell, M, et al. 2011. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgraduate Medicine. 123(4).
• Retlich, S, et al. 2009. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats. Biopharmaceutics & Drug Disposition. 30(8).
• Retlich, S, et al. 2010. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. Journal of Clinical Pharmacology. 50(8).
• Retlich, S, et al. 2010. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clinical Pharmacokinetics. 49(12).
• Ring, A, et al. 2011. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. British Journal of Clinical Pharmacology. 72(1).
• Ross, SA, et al. 2012. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion. 28(9).
• Sarashina, A, et al. 2010. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clinical Therapeutics. 32(6).
• Scheen, AJ, et al. 2011. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opinion On Drug Metabolism & Toxicology. 7(12).
• Scheen, AJ, et al. 2012. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. Revue Medicale De Liege. 67(2).
• Schernthaner, G, et al. 2012. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism. 14(5).
• Schürmann, C, et al. 2012. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. The Journal of Pharmacology and Experimental Therapeutics. 342(1).
• Scott, LJ, et al. 2011. Linagliptin: in type 2 diabetes mellitus. Drugs. 71(5).
• Singh-Franco, D, et al. 2012. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obesity & Metabolism. 14(8).
• Sutton, JM, et al. 2011. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 22(3).
• Taskinen, MR, et al. 2010. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity & Metabolism. 13(1).
• Tiwari, A, et al. 2009. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs (London, England : 2000). 10(10).
• Toth, PP, et al. 2011. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Postgraduate Medicine. 123(4).
• Traynor, K, et al. 2011. Linagliptin approved for type 2 diabetes. American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 68(12).
• Vickers, SP, et al. 2012. Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals. Clinical Laboratory. 58(7-8).
• Wright, S, et al. 2012. The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety. International Journal of Clinical Pharmacology and Therapeutics. 50(5).